8-K filing — Ensysce Biosciences, Inc. (ENSC)
Filed: 2026-08-25 AccNo: 0001493152-26-040080 Size: 204 KB Item 8.01: Other Events
Read original at edgarStocks · News reference
8-K filing — Ensysce Biosciences, Inc. (ENSC)
Filed: 2026-08-06 AccNo: 0001493152-26-036268 Size: 6 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.02: Unregistered Sales of Equity Securities Item 3.03: Material Modifications to Rights of Security Holders Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 6, 2026, 12:20 PM
- Checked
- Aug 6, 2026, 12:20 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Ensysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M Estimate
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.50) by 60 percent. This is a 74.68 percent increase over losses of $(0.79) per share from
Read original at benzingaNasdaq Down 50 Points; US Foods Posts Upbeat Earnings
US stocks trade mixed, Nasdaq falls 50 points. Energy shares up 1.3%, tech stocks down 0.5%. US Foods beats earnings, Clearone Inc surges 203%.
Read original at benzingaEnsyce Biosciences shares are trading higher after the company announced the acquisition of Cy Biopharma and up to $77 million in private financing.
Read original at benzinga